/XRTX
XRTX Stock - XORTX Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$0.60+1.59%
+$0.01 (+1.59%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.59 – $0.61
TARGET (TP)$0.69
STOP LOSS$0.55
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.10
52W High$1.79
52W Low$0.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-142,255 | $-55,525 | $-14,137 | $-16,043 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,593,464 | $-6,156,862 | $-9,874,152 | $-2,885,312 | $-1,095,755 |
| Net Income | $-4,763,564 | $-2,197,641 | $-6,997,312 | $-1,306,294 | $-1,008,321 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.65 | $-1.08 | $-4.72 | $-1.19 | $-1.73 |
Company Overview
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XRTXBeat Rate
58%
Last 12 quarters
Avg Surprise
-314.3%
EPS vs Estimate
Beats / Misses
7/5
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
-176.5%
$-1.24vs$-0.45
Q3 24
+112.0%
$0.06vs$-0.50
Q4 24
+47.8%
$-0.20vs$-0.38
Q2 25
No data
Q2 25
-359.3%
$-1.24vs$-0.27
Q3 25
+24.0%
$-0.19vs$-0.25
Q4 25
+58.9%
$-0.13vs$-0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.32 | $-0.13 | +58.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q2 2025 | May 21, 2025 | $-0.27 | $-1.24 | -359.3% | ✗ MISS |
Q2 2025 | May 10, 2025 | — | $0.03 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.38 | $-0.20 | +47.8% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.50 | $0.06 | +112.0% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.45 | $-1.24 | -176.5% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $0.92 | — | — |
Q4 2023 | Nov 14, 2023 | $-0.19 | $-6.03 | -3073.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.36 | $-0.81 | +40.4% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-1.31 | $-0.99 | +24.4% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-1.34 | — | — |
Q4 2022 | Nov 10, 2022 | $-1.54 | $-0.81 | +47.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.24 | $-0.81 | -237.5% | ✗ MISS |
Q2 2022 | Apr 12, 2022 | $-0.19 | $-0.72 | -278.9% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $5.21 | — | — |
Q4 2021 | Nov 29, 2021 | — | $-6.34 | — | — |
Q3 2021 | Aug 27, 2021 | — | $-0.17 | — | — |
Q2 2021 | Apr 27, 2021 | — | $-1.90 | — | — |
Latest News
XORTX Therapeutics shares are trading higher after the company announced it will acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystem.
📈 PositiveBenzinga•Oct 17, 2025, 01:15 PM
XORTX Expands Kidney Disease Pipeline With $3M Acquisition Of Vectus' VB4-P5 Therapeutic Program
📈 PositiveBenzinga•Oct 17, 2025, 11:10 AM
XORTX Therapeutics Issues 73,871 Shares At $1.54 In Q1 2025, Raising Net Proceeds Of $109.7K Under ATM Program
➖ NeutralBenzinga•Sep 3, 2025, 11:12 AM
XORTX Therapeutics Initiates IND Preparation For XRx-026, Focused On Treatment Of Gout
📈 PositiveBenzinga•Sep 3, 2025, 11:09 AM
Frequently Asked Questions about XRTX
What is XRTX's current stock price?
XORTX Therapeutics Inc. (XRTX) is currently trading at $0.60 per share. The stock has moved +1.59% today.
What is the analyst price target for XRTX?
No analyst price targets are currently available for this stock.
What sector is XORTX Therapeutics Inc. in?
XORTX Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XRTX's market cap?
XORTX Therapeutics Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does XRTX pay dividends?
No, XORTX Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
MLEC
Moolec Science S.A.
$0.33
Mkt Cap: $0.0B
NCEL
NewcelX Ltd.
$2.60
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to XRTX for comparison